ASH2021

4 Biotechs That Were Winners at ASH
4 Biotechs That Were Winners at ASH
Motley Fool
ASH2021
Bristol Myers Squibb
Agios Pharmaceuticals
Forma Therapeutics
Bluebird Bio
sickle cell disease
Multiple Myeloma
Flag link:
ASH 2021 movers – IGM steals the show, for all the wrong reasons
ASH 2021 movers – IGM steals the show, for all the wrong reasons
EP Vantage
ASH2021
IGM Biosciences
Flag link:
ASH: Roche's antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma
ASH: Roche's antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma
Endpoints
ASH2021
Roche
antibody-drug conjugate
Polivy
Genentech
blood cancers
Flag link:
ASH: With PhIII data in hand, Atara eyes a submission to treat a small but desperate group of transplant patients
ASH: With PhIII data in hand, Atara eyes a submission to treat a small but desperate group of transplant patients
Endpoints
ASH2021
Atara
tabelecleucel
Tab-cel
EBV
Flag link:
ASH 2021 – Bluebird looks to revive Lentiglobin
ASH 2021 – Bluebird looks to revive Lentiglobin
EP Vantage
Bluebird Bio
LentiGlobin
ASH2021
sickle cell disease
Flag link:
ASH: Sanofi, Johnson & Johnson on collision course with Sarclisa, Darzalex 4-drug regimens in myeloma
ASH: Sanofi, Johnson & Johnson on collision course with Sarclisa, Darzalex 4-drug regimens in myeloma
Fierce Pharma
ASH2021
Sanofi
JNJ
Sarclisa
Darzalex
Multiple Myeloma
Flag link:
ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio
ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio
Endpoints
ASH2021
Roche
Genentech
bispecific antibodies
blood cancer
mosunetuzumab
Flag link:
ASH: Another 'off-the-shelf' cell therapy leader shows durability issues, raising renewed concerns about emerging field
ASH: Another 'off-the-shelf' cell therapy leader shows durability issues, raising renewed concerns about emerging field
Endpoints
ASH2021
Precision Biosciences
CAR-T
relapsed or refractory non-Hodgkins lymphoma
Flag link:
ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe
ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe
Fierce Pharma
ASH2021
Servier
Tibsovo
AML
Flag link:
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
OBR Oncology
ASH2021
CAR-T
lymphoma
Yescarta
Tibsovo
blood cancers
COVID-19
AML
Flag link:
Ash 2021 preview – small increases and big falls
Ash 2021 preview – small increases and big falls
EP Vantage
ASH2021
Sanofi
fitusiran
ALX Oncology
Syndax Pharma
Global Blood Therapeutics
IGM Biosciences
Flag link:
Global Blood takes on gene therapy
Global Blood takes on gene therapy
EP Vantage
Global Blood Therapeutics
GBT021601
Oxbryta
gene therapy
ASH2021
sickle cell disease
Flag link: